Cargando…

Mathematical modeling of postmenopausal osteoporosis and its treatment by the anti-catabolic drug denosumab

Denosumab, a fully human monoclonal antibody, has been approved for the treatment of postmenopausal osteoporosis. The therapeutic effect of denosumab rests on its ability to inhibit osteoclast differentiation. Here, we present a computational approach on the basis of coupling a pharmacokinetics mode...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scheiner, S, Pivonka, P, Smith, D W, Dunstan, C R, Hellmich, C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2014
Materias:	Paper Presented at Eccomas-3MBM - Multiscale and Multiphysics Modelling in Bone Mechanobiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4291103/ https://www.ncbi.nlm.nih.gov/pubmed/24039120 http://dx.doi.org/10.1002/cnm.2584

Ejemplares similares

ODP119 Raloxifene use after denosumab discontinuation partially attenuates bone loss in the lumbar spine in postmenopausal osteoporosis
por: Hone, Namki, et al.
Publicado: (2022)

Prospects for Declarative Mathematical Modeling of Complex Biological Systems
por: Mjolsness, Eric
Publicado: (2019)

SUN-391 Denosumab Treatment of Patients with Osteoporosis and Idiopathic Hypercalciuria
por: Chu, Winston S, et al.
Publicado: (2020)

SUN-377 Efficacy of Low Dose Denosumab in Maintaining Bone Mineral Density in Postmenopausal Women with Osteoporosis: A Real World, Prospective Observational Study
por: Khan, Aliya Aziz, et al.
Publicado: (2020)

OR13-06 Romosozumab After Denosumab Improves Lumbar Spine Bone Mineral Density And Microarchitecture Greater Than Denosumab Continuation In Postmenopausal Women
por: Hong, Namki, et al.
Publicado: (2023)

FRI685 Denosumab Withdrawal Is Associated With Hypercalcemia In Adults With Osteoporosis And Bone Metastases
por: Patil, Madhuri D, et al.
Publicado: (2023)

Development and validation of a gene signature predicting the risk of postmenopausal osteoporosis
por: Yuan, Wei, et al.
Publicado: (2022)

Emerging treatments for postmenopausal osteoporosis – focus on denosumab
por: Geusens, Piet
Publicado: (2009)

Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis
por: Lewiecki, E Michael
Publicado: (2011)

Denosumab: an investigational drug for the management of postmenopausal osteoporosis
por: Lewiecki, E Michael
Publicado: (2008)

Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis
por: Min, Yong-Ki
Publicado: (2015)

Denosumab versus romosozumab for postmenopausal osteoporosis treatment
por: Kobayakawa, Tomonori, et al.
Publicado: (2021)

OR01-5 Transition From Low Dose Denosumab 30mg to IV Zoledronic Acid: Effect on Bone Mineral Density in Postmenopausal Women with Osteoporosis: A Prospective Observational Study
por: Ibrahim, Quazi, et al.
Publicado: (2022)

Multiscale Experiments and Modeling in Biomaterials and Biological Materials, Part I
por: Du, Jing, et al.
Publicado: (2021)

Differences in Interactions Within Viral Replication Complexes of SARS-CoV-2 (COVID-19) and SARS-CoV Coronaviruses Control RNA Replication Ability
por: Faisal, H. M. Nasrullah, et al.
Publicado: (2021)

Multiscale Experiments and Modeling in Biomaterials and Biological Materials, Part II
por: Du, Jing, et al.
Publicado: (2021)

Self-Organized Morphology and Multiscale Structures of CoVE Proteins
por: Sompornpisut, Pornthep, et al.
Publicado: (2021)

SUN-512 Denosumab Improves Trabecular but Not Cortical Bone Osteoporosis in a Patient with Refractory Primary Hyperparathyroidism
por: Alhassan, Sharifa, et al.
Publicado: (2019)

Efficacy of Low Dose Denosumab in Maintaining Bone Mineral Density in Postmenopausal Women With Osteoporosis Switching From 60mg to 30mg 6 Monthly: A Real World, Prospective Observational Study
por: Khan, Aliya, et al.
Publicado: (2021)

Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain
por: Darbà, Josep, et al.
Publicado: (2015)

Denosumab – a new medication in the treatment of postmenopausal osteoporosis
por: Słopień, Radosław, et al.
Publicado: (2017)

Update on denosumab in the management of postmenopausal osteoporosis: patient preference and adherence
por: Cairoli, Elisa, et al.
Publicado: (2015)

Cost-Effectiveness of Denosumab for the Treatment of Postmenopausal Osteoporosis in South Korea
por: Kang, Jung-Yoon, et al.
Publicado: (2022)

SUN-LB65 Circulating Micrornas Linked to Bone Metabolism Are Affected by Sequential Anti Osteoporotic Treatment in Postmenopausal Osteoporosis
por: Yavropoulou, Maria, et al.
Publicado: (2020)

A poroelastic mixture model of mechanobiological processes in biomass growth: theory and application to tissue engineering
por: Sacco, Riccardo, et al.
Publicado: (2017)

MON-LB71 Adult Hypophosphatasia and Postmenopausal Osteoporosis: A Challenging Case
por: Abramof-Ness, Rosane, et al.
Publicado: (2020)

Adapting a Plant Tissue Model to Animal Development: Introducing Cell Sliding into VirtualLeaf
por: Wolff, Henri B., et al.
Publicado: (2019)

Are Homeostatic States Stable? Dynamical Stability in Morphoelasticity
por: Erlich, Alexander, et al.
Publicado: (2018)

Melatonin induces RAW264.7 cell apoptosis via the BMAL1/ROS/MAPK-p38 pathway to improve postmenopausal osteoporosis
por: Wang, Xiaochuan, et al.
Publicado: (2023)

Femoral and Vertebral Strength Improvements in Postmenopausal Women With Osteoporosis Treated With Denosumab
por: Keaveny, Tony M, et al.
Publicado: (2014)

Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis
por: Wu, Jiaqi, et al.
Publicado: (2018)

Efficacy and Safety of Denosumab in Postmenopausal Women With Osteoporosis: A Meta-Analysis
por: Gu, Hai-Feng, et al.
Publicado: (2015)

Real-world cost-effectiveness of denosumab for the treatment of postmenopausal osteoporosis in Taiwan
por: Johnson, Ben, et al.
Publicado: (2021)

Economic Evaluation of Denosumab for Treatment of Postmenopausal Osteoporosis: A Systematic Review
por: Nargesi, Shahin, et al.
Publicado: (2022)

Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?
por: Watts, N. B., et al.
Publicado: (2011)

SAT-499 Denosumab for Treatment of Hypercalcemia in Myelofibrosis
por: Wong, Beatrice, et al.
Publicado: (2019)

MON-356 Atypical Femur Fracture with Denosumab
por: Mirza, Faryal S, et al.
Publicado: (2020)

ODP085 Denosumab Induced Severe Hypophosphatemia
por: Del Mar Morales Hernandez, Maria, et al.
Publicado: (2022)

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates
por: Miller, P. D., et al.
Publicado: (2016)

Compliance and discontinuation of denosumab treatment in postmenopausal Japanese women with primary osteoporosis or rheumatoid arthritis and osteoporosis
por: Suzuki, Takako, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ojhjcu1k4gnbo5caj21uocj4fq